AU2020260470A1
|
|
Method for evaluating the effects of a composition comprising microorganisms on intestinal microbiota
|
WO2020250209A2
|
|
Lactoferrin for oral use with antiviral action
|
WO2021053641A2
|
|
Compositions based on bacterial strains and berry extracts and their use as anti-inflammatories
|
WO2021053639A1
|
|
Bacterial strains, their compositions and their use for the treatment of gastrointestinal disorders
|
WO2021053642A1
|
|
Compositions based on bacterial strains and their use as anti-inflammatories
|
WO2021053636A1
|
|
Bacterial strains, their compositions and their use for the treatment of gastrointestinal disorders
|
WO2021005529A1
|
|
Bifidobacterium bifidum bacterial strain, the compositions thereof and related uses
|
WO2020245784A1
|
|
Composition for use in a method for prevention or treatment of maltnutrition in a subject suffering from a chronic inflammatory bowel diseases
|
WO2020084589A1
|
|
Bacterial strains of the lactobacillus paracasei species for use, oral or topical, in the treatment of disorders of the female urogenital tract
|
WO2019111189A1
|
|
Composition based on probiotics and uses thereof
|
CA3075235A1
|
|
New use for treatment of clostridium difficile infections
|
IT201800007928A1
|
|
Composition containing a mucolytic agent for the treatment of mucus hypersecretion and a device for its dosage
|
IT201800007527A1
|
|
Composition containing beclomethasone for the prevention and treatment of bacterial prostatitis and vaginitis
|
AU2017377139A1
|
|
Probiotics for use in the treatment of diverticulosis and diverticular disease
|
AU2017367302A1
|
|
Exopolysaccharides and uses thereof
|
CN109310719A
|
|
The new medical application of probiotics
|
CN110191647A
|
|
Prebiotics are used to improve the purposes of protein adsorption
|
WO2017195182A1
|
|
Use of probiotics for improving protein absorption
|
WO2017175123A1
|
|
Process for mesalazine solid formulations
|
IT201600122310A1
|
|
Composition for use in the treatment of bowel disorders
|